Skip to main content
Signal8

ALTERITY THERAPEUTICS LTD (PRNAF)

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Alterity Therapeutics Limited logo

Alterity Therapeutics Limited

OTC:PRNAFSub-class of ATHEHealthcare
+0.00%$0.2000
CLOSED
Mkt Cap$3.82M
EV-
Float-
O/S19.09M
VOL3K sh
$ Vol$500
RVOL0.50×
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
Alterity Therapeutics Limited logoOTC:PRNAFClosed$0.2000+0.00%
FormDescription
6-K
6-K
6-K
6-K
6-K
6-K
6-K
6-K
6-K
6-K
6-K
6-K
S-8
SEC Filing
6-K
6-K
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
6-K
6-K
6-K
6-K
6-K
6-K
6-K
6-K

1-25 of 1,173

…
    Alterity Therapeutics Ltd (PRNAF) SEC Filings | Signal8